Top Story

VIDEO: Results of LEADER trial provide “robust demonstration” of cardiovascular event reduction in high-risk type 2 diabetes

July 1, 2016

NEW ORLEANS — In this video, Michael T. McDermott, MD, director of endocrinology and diabetes practice at the University of Colorado Hospital, discusses the results of the LEADER trial, which demonstrated that the use of liraglutide reduced the risk for cardiovascular death, nonfatal myocardial infarction and stroke in patients with type 2 diabetes and a history of cardiovascular disease.

FDA NewsPerspective

FDA advisory committee splits on CV benefit claim for Jardiance

June 28, 2016
An FDA advisory panel on Tuesday voted 12 to 11 in favor of an expanded indication for the SGLT2 inhibitor Jardiance, supporting language in the prescribing information…
Meeting News Coverage

Actos reduces type 2 diabetes risk in adults with prediabetes, prior stroke

June 16, 2016
NEW ORLEANS — The risk for developing type 2 diabetes, especially among those with prediabetes and/or who have had strokes may be reduced with the PPAR agonist…
FDA News

FDA strengthens kidney warnings on Invokana, Farxiga labels

June 14, 2016
The FDA issued a drug safety communication stating that it has revised the warning labels of SGLT2 inhibitors Invokana/Invokamet and Farxiga/Xigduo XR to include…
In the Journals

Sugar-sweetened beverages associated with increased visceral fat

January 12, 2016
Regular consumption of sugar-sweetened beverages has been linked to a higher volume of visceral adipose tissue. Caroline Fox, M D

In the Journals

ACE inhibitors, angiotensin receptor blockers yield similar efficacy, safety in patients without HF

January 7, 2016
Angiotensin receptor blockers are as safe and effective as ACE inhibitors in patients without heart failure, with the added advantage of better…

Meeting News CoverageVideo

VIDEO: Positive CV outcomes with SGLT2 inhibitors mark ‘an exciting time’

January 7, 2016
ORLANDO, Fla. — Raymond R. Townsend, MD, of the University of Pennsylvania in Philadelphia, discusses the promise of sodium-glucose…

Meeting News CoverageVideo

VIDEO: Data on smoking cessation, diabetes therapies promising for CVD prevention

January 5, 2016
ORLANDO, Fla. — Pamela B. Morris, MD, associate professor of medicine at the Medical University of South Carolina and chair of the American…

A paradigm shift in BP management: Results of SPRINT and other recent trials

January 4, 2016
by Haitham M. Ahmed, MD, MPH; Seamus P. Whelton, MD, MPH; and Roger S. Blumenthal, MD In 2015, we have seen groundbreaking updates in the treatment…

In the Journals

Bariatric surgery reduces diabetes, myocardial infarction risks

December 22, 2015
The risks for type 2 diabetes and myocardial infarction were reduced with bariatric surgery, according to recent study findings published in…


Secondary Prevention of Atherothrombotic Events: Current Insights on Advancing Science

December 23, 2015 Expires: 12/22/2016
Prevention of cardiovascular disease (CVD) is critical in light of its associated mortality, morbidity, and economic burden. Preexisting conditions –…

This activity is supported by an educational grant from Merck & Co.

FDA News

REMS no longer needed for medicines containing rosiglitazone

December 16, 2015
The FDA today announced that it is eliminating the Risk Evaluation and Mitigation Strategy for rosiglitazone-containing type 2 diabetes medications. …

In the Journals

Metformin may improve CV risk profile in patients at risk for diabetes

December 16, 2015
Four months of metformin therapy modestly improved the cardiovascular risk profile in patients with ST-elevation myocardial infarction, or STEMI, at…

Meeting News CoverageVideo

VIDEO: Daniel P. Kelly, MD, details ‘vicious cycle’ between obesity, diabetes and CVD

December 15, 2015
ORLANDO, Fla. — Daniel P. Kelly, MD, scientific director at the Sanford Burnham Prebys Medical Discovery Institute in Orlando, Florida, delves…

More Headlines »